JMJacques Moret

Jacques Moret

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacques Moret has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Residual shunting and delayed neoangiogenesis after endovascular treatment of vein of Galen aneurysmal malformations: Long-term angiographic cohort study

    by Taisuke Akimoto, Marta Iacobucci, Vanessa Chalumeau, Jonathan Cortese, Cristian Mihalea, Ikka Léon, Jordi Miatello, Ramy Charbel, Luc Morin, Pierre Tissieres, et al.

    Background Long-term angiographic stability after endovascular treatment of vein of Galen aneurysmal malformations (VGAMs) remains incompletely characterized. We evaluated the incidence and timing of delayed neoangiogenesis after incomplete angiographic occlusion. Methods A predefined single-center imaging cohort of 34 patients with VGAM who had baseline diagnostic angiography and long-term follow-up imaging was analyzed. Neoangiogenesis was defined as delayed newly recruited arterial feeders or vascular networks absent on baseline angiography. Time-to-event analyses were performed using Kaplan–Meier estimates. The primary analysis excluded patients with ≥20 years of angiographic follow-up; full-cohort and ≥5 year follow-up sensitivity analyses were performed. Results Complete angiographic cure was achieved in nine patients (26.5%). Neoangiogenesis occurred in 19 patients (55.9%) and exclusively in those without angiographic cure. In the primary cohort with Conclusions In this imaging-adjudicated cohort, residual shunting after VGAM embolization was associated with delayed neoangiogenesis, whereas angiographic cure was associated with durable vascular stability. Residual shunting should not be considered a stable angiographic endpoint but a potential substrate for late vascular remodeling. Long-term imaging surveillance, with repeat catheter angiography when interval vascular change is suspected, should be considered.

  • Lost in translation: Gaps in multidimensional assessment undermine the role of clot histology in thrombectomy—An expert roadmap and meta-analytic review

    by Mohamed F. Doheim, David Bouchez, Christophe Cognard, Mikaël Mazighi, Vitor Mendes Pereira, Jacques Moret, Laurent Spelle, Raul G. Nogueira

  • Counterpoint: The important educational value of live surgical broadcasts

    by Demetrius Klee Lopes, Ricardo A Hanel, Elad I Levy, H Saruhan Cekirge, Pedro Lylyk, Isil Saatci, Jianmin Liu, Naci Kocer, Charbel Mounayer, Osman Kizilkilic, et al.

    At most major academic centers, the stress of performing a procedure under scrutiny from faculty, mentees, and other observers is the norm, rather than the exception. There is no perceived additional stress to those who do this day in and day out with observers. Similarly, at most major centers with multiple neurointerventionalists, it is routine for their partners to join in cases, be consulted during a case, or offer opinions during a complex case or complication management, with or without solicitation. Their opinions are usually valued and entertained and at other times ignored as the primary physician manages the case as deemed necessary. This is all routine, commonplace, and a daily occurrence.


  • Open Access

    Aneurysm Treatment with Woven EndoBridge-17: Angiographic and Clinical Results at 12 Months from a Retrospective, 2-Center Series

    by P. Pagano, J. Cortese, S. Soize, J. Caroff, P.F. Manceau, J. Moret, L. Spelle, L. Pierot

    BACKGROUND AND PURPOSE: This retrospective, 2-center study investigated the feasibility, safety, and efficacy at 12-month follow-up of the treatment of ruptured, unruptured, and recurrent intracranial aneurysms using the latest generation of the Woven EndoBridge (WEB) device, the WEB-17 system. MATERIALS AND METHODS: Aneurysms treated with WEB-17 were extracted from the databases of 2 neurovascular centers. Patients, aneurysm characteristics, complications, and clinical and anatomic results were analyzed. RESULTS: From February 2017 to May 2021, two hundred twelve patients with 233 aneurysms (181/233, 77.7%, unruptured-recurrent, and 52/233, 22.3%, ruptured) were included. High treatment feasibility (95.3%) was reported and was similar in ruptured aneurysms (94.2%) and unruptured-recurrent aneurysms (95.6%) (P = .71) and in typical (95.4%) and atypical (94.7%) locations (P = .70), but it was lower in aneurysms with an angle between the parent artery and main aneurysm axis of ≥45° (90.2%) compared with those with an angle of P = .03). Global mortality and morbidity were 1.9% and 3.8% at 1 month, respectively, and 4.4% and 1.9% at 12 months, respectively. One-month morbidity (P = .02) and mortality (P = .003) were higher in the ruptured group (10.0% and 8.0%, respectively) compared with unruptured-recurrent group (1.9% and 0.0%, respectively). Overall adequate occlusion (complete occlusion and neck remnant) was 86.3%. The percentage of adequate occlusion was higher (P = .05) in the unruptured-recurrent group (88.5%) compared with the ruptured group (77.5%). CONCLUSIONS: The WEB-17 system showed high feasibility for ruptured and unruptured aneurysms, typical and atypical locations, and some aneurysms with an angle of ≥45°. As the most recent generation device, the WEB-17 also demonstrates high safety and good efficacy.


  • Open Access

    Persistent Opacification of the Woven EndoBridge Device: A Conebeam CT Analysis of the Bicêtre Occlusion Scale Score 1 Phenomenon

    by J. Caroff, S.D. Popescu, C. Mihalea, D.A. Popica, L. Ikka, S. Gallas, A. Ozanne, V. Chalumeau, J. Moret, J. Cortese, et al.

    BACKGROUND AND PURPOSE: Some Woven EndoBridge devices present a persistent intradevice opacification at imaging follow-up, described as the Bicêtre Occlusion Scale Score 1 (BOSS 1) phenomenon. The clinical implications remain unknown. We aimed here to analyze the factors influencing this occurrence and to precisely describe the evolution of BOSS 1 with time using conebeam CT. MATERIALS AND METHODS: We retrospectively analyzed a prospectively maintained Woven EndoBridge database at our tertiary center and included all patients with isolated BOSS 1 and BOSS 1 associated with small neck remnant (BOSS 1 + 2). RESULTS: Two hundred sixty-seven aneurysms were treated with a Woven EndoBridge device between July 2012 and December 2021. Follow-up with DSA was available for 220 aneurysms (median, 5 months), among which BOSS 1 and 1 + 2 were found in 9.1% (20/220) (95% CI, 5.5%—12.7%). A second DSA follow-up (median, 17 months) was performed in 15 of these 20 aneurysms, which revealed that 40% had evolved to complete Woven EndoBridge occlusion, 33% showed a decreased persistent opacification, and 27% remained stable. BOSS 1 was significantly associated with postoperative antiplatelet medication, a lower aneurysm aspect ratio, and the use of the Woven EndoBridge 17 (P  < .05). The average Woven EndoBridge shape modification was less pronounced in the BOSS 1 population (P  < .02). None of the BOSS 1 or 1 + 2 aneurysms required retreatment or were associated with hemorrhage occurrence. CONCLUSIONS: Isolated persistent flow inside the Woven EndoBridge device at follow-up is rare and notably associated with antiplatelet prescription. It seems to present a benign course in most cases.


  • Impact of A1 Asymmetry on the Woven EndoBridge Device in Anterior Communicating Artery Aneurysms

    by J. Cortese, J. Caroff, J.-B. Girot, C. Mihalea, V. Da Ros, G. Aguiar, A. Elawady, L. Ikka, S. Gallas, A. Ozanne, et al.

    BACKGROUND AND PURPOSE: Woven EndoBridge (WEB) devices are increasingly used to treat intracranial aneurysms. A1 asymmetry contributes to anterior communicating artery aneurysm formation and to treatment instability after coiling. We sought to evaluate whether A1 asymmetry had an impact on angiographic outcome in anterior communicating artery aneurysms treated with the WEB. MATERIALS AND METHODS: Anterior communicating artery aneurysms treated between July 2012 and July 2020 with the WEB from an institutional review board–approved database were reviewed. A1 asymmetry was categorized as the following: absence of the A1 segment on 1 side (unilateral A1) versus bilateral A1. Univariate and multivariable analyses assessed independent predictors of adequate (WEB Occlusion Scale A, B, and C) and complete occlusion (WEB Occlusion Scale A and B). RESULTS: Forty-eight individual aneurysms (47 patients) were included in the final analysis, of which 16 (33%) were acutely ruptured. The mean size was 6.5 (SD, 2.2) mm. Adequate and complete occlusion was achieved in 33 (69%) and 30 (63%) cases, respectively. Unilateral A1 was associated with significantly higher rates of adequate (92% versus 60% for bilateral A1; P = .03) and complete occlusion (92% versus 50% for bilateral A1; P < .01). Multivariable logistic regression confirmed unilateral A1 as an independent predictor of both adequate (OR = 10.6; 95% CI, 1.6–220.7; P = .04) and complete occlusion (OR = 9.5, 95% CI, 1.5–190.2; P = .04. A sensitivity analysis comparing unilateral “functional” A1 with bilateral “functional” A1 showed similar results. WEB shape modification was not influenced by the unilateral A1 configuration (P = .70). CONCLUSIONS: Anterior communicating artery aneurysms with a unilateral A1 configuration treated with WEB devices are associated with better angiographic outcome than those with bilateral A1. This finding supports the hypothesis that WEB devices are resistant to unilateral flow in the aneurysm as opposed to coils.


  • Endovascular Treatment of Small and Very Small Intracranial Aneurysms with the Woven EndoBridge Device

    by J.-B. Girot, J. Caroff, J. Cortese, C. Mihalea, A. Rouchaud, V.DA Ros, J.V. Martinez, L. Contreras, L. Ikka, V. Chalumeau, et al.

    BACKGROUND AND PURPOSE: The Woven EndoBridge has proved to be a safe and effective treatment, especially for wide-neck intracranial aneurysms. The recent fifth-generation Woven EndoBridge came with smaller devices. The purpose of this study was to assess the safety and efficiency of Woven EndoBridge treatment of small and very small aneurysms. MATERIALS AND METHODS: Between September 2017 and March 2020, all consecutive patients treated with a 3- or 3.5 mm-width Woven EndoBridge device were included in this retrospective intention-to-treat study. Clinical and radiologic findings were evaluated at immediate and last-available follow-up. Angiographic outcome was assessed by an external expert reader. RESULTS: One hundred twenty-eight aneurysms were treated with a fifth-generation Woven EndoBridge device including 29 with a width of ≤3.5 mm. Ten aneurysms were ruptured (34%). In 3 cases (10%), Woven EndoBridge treatment could not be performed because the aneurysm was still too small for the smallest available Woven EndoBridge device and another endovascular strategy was chosen. The median follow-up time was 11.2 months. Complete and adequate occlusion was obtained in 71% and 90% of the treated aneurysms, respectively. Retreatment was needed in 2 cases (10%). Symptomatic ischemic complications leading to transient neurologic deficits occurred in 2 cases (7%) (1 procedure-related and 1 device-related) but with full spontaneous recovery at discharge. CONCLUSIONS: The fifth-generation Woven EndoBridge device seems to be a safe and technically feasible treatment for both ruptured and unruptured small and very small intracranial aneurysms, with satisfactory occlusion rates on midterm follow-up. However, further study is needed to evaluate longer-term efficiency.


  • Y-stenting with braided stents for wide-neck intracranial bifurcation aneurysms. A single-center initial experience

    by Cristian Mihalea, Jildaz Caroff, Leon Ikka, Nidhal Benachour, Valerio Da Ros, Hazem Abdelkhalek, Marta Iacobucci, Joaquin Jose Marenco de la Torre, Igor Pagiola, Thomas Yasuda, et al.


  • Open Access

    WEB Device: Ready for Ruptured Aneurysms?

    by J. Caroff, J. Moret, L. Spelle

    We read with great interest the article by van Rooij et al entitled “WEB Treatment of Ruptured Intracranial Aneurysms: A Single-Center Cohort of 100 Patients.”[1][1] Following our first report on the use of Woven EndoBridge devices (WEB; Sequent Medical, Aliso Viejo, California) for ruptured


  • Open Access

    Large Basilar Apex Aneurysms Treated with Flow-Diverter Stents

    by V. Da Ros, J. Caroff, A. Rouchaud, C. Mihalea, L. Ikka, J. Moret, L. Spelle

    BACKGROUND AND PURPOSE: The treatment of wide-neck, large basilar apex aneurysms is challenging with either an endovascular or a surgical approach. The aim of the present study was to report our experience treating basilar apex aneurysms with flow-diverter stents and to evaluate their efficacy and safety profile in this specific anatomic condition. MATERIALS AND METHODS: We retrospectively analyzed data from all consecutive patients treated with flow-diverter stents at our institution between January 2011 and January 2015. Patients with large basilar apex aneurysms treated with a flow-diverter stent were included in the study. Clinical presentations, technical details, intra- and perioperative complications, and clinical and angiographic outcomes were recorded, with a midterm follow-up. RESULTS: Of the 175 aneurysms treated with flow-diverter stents at our institution, 5 patients (2 women and 3 men; age range, 44–58 years) received flow-diverter stent for basilar apex aneurysms. The mean follow-up after stent deployment was 21 months (range, 15–24 months). One patient died on day 31 from an early postprocedural midbrain hemorrhage. One patient had a right cerebellar hemispheric ischemic lesion with a transient cerebellar syndrome resolved within 24 hours without neurologic sequelae at the latest follow-up. The mRS was 0 in 4 patients and 6 in 1 patient at last follow-up. CONCLUSIONS: Flow diversion is a feasible technique with an efficacy demonstrated at a midterm follow-up, especially in the case of basilar apex aneurysm recurrences after previous endovascular treatments. Concern about its safety profile still exists.